Exelixis, Inc.EXEL announced that it has started submitting a rolling new drug application (NDA) to the FDA for its oncology drug Cometriq (cabozantinib). The company is looking to get Cometriq approved for the treatment of patients suffering from advanced
Exelixis Starts Cometriq Rolling NDA Filing for Kidney Cancer
